Stifel raised the firm’s price target on Guardant Health (GH) to $53 from $45 and keeps a Buy rating on the shares. Q4 revenue beat expectations and management’s outlook for 2025 sales is above the Street view to start the year, the analyst tells investors. The relative attractiveness of Guardant “when compared to names with academic and China exposure doesn’t hurt either,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $56 from $42 at TD Cowen
- Guardant Health price target raised to $59 from $39 at Raymond James
- Guardant Health price target raised to $60 from $55 at BTIG
- Guardant Health price target raised to $56 from $49 at Guggenheim
- Guardant Health’s Promising Growth Prospects: Buy Rating Backed by Strong Revenue Guidance and Optimistic Projections